Mi Dendream,
I really believe that Dr. Liau is coordinating all that she's doing with NWBO and they will supply corporate support for her efforts. If this were a normal ASCO, they'd probably sponsor a reception for her after the presentations and wine and dine those interested in attending. Year's ago a fellow investor in IMGN scored a pretty nice polo shirt by attending such a reception.
I would suspect that once TLD and peer review has occurred, the company with the cooperation of Dr. Liau will be getting a great deal of media coverage, some they'll probably be paying for. Today I doubt if .01% of the investing public have ever heard of NWBO. I expect that if we present at ASCO, by 2 weeks after ASCO 25% to 50% of the investing public will have heard the name. I really don't care how high the price of the stock is, there will be people who want to get in who'll put in buy market orders, these people won't care how many shares are outstanding or how high the market cap has become, they'll just want to be part of the company. The question is, how many here now will sell to take the price others are willing to offer.
As I see it, I'll consider how much I'll pay in taxes on the gain, and if I believe the price will retrench sufficiently to repurchase the shares I sell, and then some, I'll probably do so with at least part of my holdings. Certainly what's in the Roth IRA's will go as no tax burden will be felt with it.
Of course it's possible we're wrong about ASCO, maybe it will be a Journal, while I don't believe it will have the impact, over time the investment public will learn the potential of what we have. The real potential frankly won't be known until more trials have been done on a variety of cancers and with DCVax-Direct as well, that could be many years, but investors should know the potential may be far more than helping GBM patients.
Gary
News 
Market Data 
Discover 
